In Other Journals

Ann Gregory
Med J Aust 2006; 184 (12): . || doi: 10.5694/j.1326-5377.2006.tb00425.x
Published online: 19 June 2006

The cardiovascular risks associated with rofecoxib use are more acute than previously thought, according to Canadian researchers. Levesque and colleagues analysed data from 526 patients aged 66 years or older who were current users of either rofecoxib (n = 239) or celecoxib (n = 287) and who had had a first acute myocardial infarction (MI) during an average follow-up period of 2.4 years. The risk of a first MI was highest following first-time use of rofecoxib — about a quarter of those who had an MI experienced it within the first few weeks of use, corresponding to the highest period of risk for this agent.

  • Ann Gregory



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.